ThreatConnect Releases Risk Quantifier™ 6.0 — Driving Continued Innovation in Cyber Risk Quantification
18.10.2021 13:30:00 EEST | Business Wire | Press release
ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification.
ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years.
With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one platform.
FAIR is an internationally known standard that has helped companies with awareness and understanding of cyber risk quantification. Organizations implementing FAIR in their CRQ programs have struggled with subjectivity, speed, and actionability, which is why RQ 6.0 is introducing semi-automated FAIR scenario’s that automate a large portion of FAIR in order to reduce complexity and increase time to value for customers.
Semi-Automated FAIR scenarios tackle one of the most challenging aspects of cyber risk quantification - calculating Loss Event Frequency and it’s piece parts. RQ combines data from inside the organization with its own models to evaluate attacker capability against defender strength. Applying this automated calculation to FAIR provides actionable, data-driven results within the FAIR framework and helps organizations transform their manual processes into the scalable, defensible needed to manage the complex risks they face.
“We’ve heard from customers, partners and the broader industry that solutions are needed to address the challenges in adopting and benefiting from CRQ programs,” said ThreatConnect Vice President of Cyber Risk Strategy Gerald Caponera. “Now, through the automation of part of FAIR, organizations can quickly adopt and advance their CRQ programs using their own data combined with ThreatConnect’s analytical capabilities.”
Using a risk-led approach to cybersecurity makes prioritization easy for security teams, enabling them to filter out noise and focus on what matters most. With CRQ, TIP and SOAR capabilities combined, ThreatConnect unifies the actions of the security team around the most critical risks, supports their response with streamlined and automated workflows and strengthens the entire security ecosystem through powerful technology integrations.
Additional details of the release are further outlined in a new blog and video available on the ThreatConnect web site. For more information – click here.
About ThreatConnect
ThreatConnect, Inc. provides cybersecurity software that reduces complexity for everyone, makes decision making easy by turning intelligence into action, and integrates processes and technologies to continually strengthen defenses and drive down risk. Designed by analysts but built for the entire team (security leadership, risk, security operations, threat intelligence, and incident response), ThreatConnect’s decision and operational support platform is the only solution available today with cyber risk quantification, intelligence, automation, analytics, and workflows in one. To learn more about our Cyber Risk Quantification, Threat Intelligence Platform (TIP) or Security Orchestration, Automation, and Response (SOAR) solutions, visit www.ThreatConnect.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005045/en/
Contact information
Levick U.S.
Maria Stagliano
Phone: +1 202.973-5341
ThreatConnect@levick.com
Lewis U.K.
Jessica Collings
Phone: +44 207.802.2626 | Fax: +44 207.802.2627
hellolondon@teamlewis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
